About Den Mark Pharmaceuticals
Den Mark Pharmaceuticals is a Healthcare company. Pharmaceutical contract manufacturing and global services in India. Den Mark Pharmaceuticals has raised $719.96 thousand across 1 funding round. The company has 137 employees. Its Indian entity Den Mark Pharmaceuticals Private Limited reported revenue of ₹23.71 Cr. Den Mark Pharmaceuticals offers products and services including Capsules and Tablets. Its focus areas include Pharmaceuticals, Manufacturing, Contract Manufacturing and Exports.
Company details
Den Mark Pharmaceuticals is recognized for providing third-party contract manufacturing services tailored for pharmaceutical companies in India and abroad. The facility in Roorkee, India, spans over 66,000 square feet and is equipped with advanced infrastructure, including segregated blocks for different medicine groups and certifications like WHO-GMP and ISO 9001:2015. Services encompass dossier preparation, registration support, technology transfer, and global exports, with a commitment to quality assurance and innovation in healthcare. Operations are guided by experienced leadership, ensuring compliance and efficiency in production.
- Employees 137
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Legal Name Den Mark Pharmaceuticals Pvt. Ltd
- Date of Incorporation 25 Nov, 2021
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹23.71 Cr
FY 2024 · +317% YoY
- Indian entity net loss-₹15.96 Cr
FY 2024 · -67% margin
- Indian entity EBITDA-₹13.52 Cr
FY 2024 · -57% margin
- Total Equity Funding$719.96K (USD)
in 1 rounds
- Latest Funding Round$719.96K (USD), Seed
Nov 2023
- Employee Count137
Associated legal entities of Den Mark Pharmaceuticals
Den Mark Pharmaceuticals operates through Den Mark Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Den Mark Pharmaceuticals Private Limited CIN U24304MH2021PTC372188 | Active | 25 Nov 2021 | Mumbai, Maharashtra | ₹23.7 Cr | 137 | 2 | View details |
Products & Services of Den Mark Pharmaceuticals
Den Mark Pharmaceuticals offers a comprehensive portfolio of products and services, including Capsules and Tablets.
Capsules are produced as part of the range for third-party contract manufacturing services.
Tablets are manufactured to meet the needs of pharmaceutical marketing companies.
Funding Insights of Den Mark Pharmaceuticals
Den Mark Pharmaceuticals has successfully raised a total of $719.96K through 1 strategic funding round. The most recent funding activity was a Seed round of $719.96 thousand completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $719,957
- Total Rounds 1
- Last Round Seed — $719,957
- First Round $719,957
(Nov 2023)
All 1 funding rounds of Den Mark Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | $719,957 | Seed | – | – | – |
Board of directors of Den Mark Pharmaceuticals Private Limited (Den Mark Pharmaceuticals)
Den Mark Pharmaceuticals Private Limited is the primary company behind Den Mark Pharmaceuticals. The board of Den Mark Pharmaceuticals Private Limited currently have 2 directors; the longest-serving is Samad Hussain Patanwala, appointed in 2021. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Samad Hussain Patanwala DIN 05147417 | Director | 25 Nov 2021 | 4 yrs 11 mo | Den Mark Pharmaceuticals Private Limited |
| Shahnazar DIN 07359481 | Director | 04 Apr 2022 | 4 yrs 6 mo | Den Mark Pharmaceuticals Private Limited |
People of Den Mark Pharmaceuticals
8 people are tracked at Den Mark Pharmaceuticals (5 in leadership, 3 in team); the tracked headcount is 137.
| Name | Role | Group |
|---|---|---|
| Founder | Leadership | |
Amged Sirelkatim Mohammad | General Manager | Leadership |
Shahnazar Ali | Plant Head | Leadership |
Narayan Sangem | Administration Head | Leadership |
Aiman Ansari | Domestic Sales Head | Leadership |
Adiba Akhamaldheiva | Purchase Manager | Team |
Gulam Shaikh | International Business | Team |
Mohammed Sajid | Senior Business Development Executive | Team |
Complete people profiles for Den Mark Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Den Mark Pharmaceuticals
Figures of Den Mark Pharmaceuticals Private Limited, the primary company behind Den Mark Pharmaceuticals, for FY 2024. Revenue was ₹23.71 Cr (+317% year on year). Net loss was -₹15.96 Cr (-67% margin). EBITDA was -₹13.52 Cr (-57% margin).
- ₹23.71 CrRevenue · FY 2024 · +317% YoY
- -₹15.96 CrNet loss · -67% margin
- -₹13.52 CrEBITDA · -57% margin
- ₹44.7 LakhPaid-up capital
- 137Employees (provident fund records)
Balance sheet, profit and loss, cash flow and ratios of Den Mark Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Den Mark Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Den Mark Pharmaceuticals
Den Mark Pharmaceuticals is a funded company, having raised a total of $719.96K across 1 funding round to date. The company's 1st funding round was a Seed of $719.96K, raised on Nov 2023.
Den Mark Pharmaceuticals has 137 employees.
The primary company behind Den Mark Pharmaceuticals, Den Mark Pharmaceuticals Private Limited, reported revenue of ₹23.71 Cr for FY 2024, up 317% year on year.
Den Mark Pharmaceuticals is recognized for providing third-party contract manufacturing services tailored for pharmaceutical companies in India and abroad. The facility in Roorkee, India, spans over 66,000 square feet and is equipped with advanced infrastructure, including segregated blocks for different medicine groups and certifications like WHO-GMP and ISO 9001:2015. Services encompass dossier preparation, registration support, technology transfer, and global exports, with a commitment to quality assurance and innovation in healthcare. Operations are guided by experienced leadership, ensuring compliance and efficiency in production.
Den Mark Pharmaceuticals offers Capsules and Tablets.
Den Mark Pharmaceuticals operates through Den Mark Pharmaceuticals Private Limited.
The legal entities of Den Mark Pharmaceuticals currently have 2 directors, including Samad Hussain Patanwala, Shahnazar.